Final results from a real world evidence study on the treatment of migraine patients with Erenumab In GERMANY (SPECTRE)

被引：0
|
作者：
Gaul, C. [1 ]
Koch, M. [2 ]
Baufeld, C. [3 ]
机构：
[1] Headache Ctr, Frankfurt, Germany
[2] Novartis Pharma AG, Basel, Switzerland
[3] Novartis Pharma GmbH, Nurnberg, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-036
引用
收藏
页码：193 / 193
页数：1
相关论文
共 50 条
  • [21] Effectiveness and safety of erenumab, galcanezumab and fremanezumab in migraine: real world data results
    Castano-Amores, C.
    Nieto-Gomez, P.
    Alvarez-Sanchez, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (03) : 819 - 820
  • [22] First insights in real-world effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry
    Peikert, Andreas
    Koerwer, Monika
    Tozzi, Viola
    Dikow, Heidi
    Rossnagel, Fabian
    Schnabel, Silvio
    Braune, Stefan
    Bergmann, Arnfin
    NEUROLOGY, 2020, 94 (15)
  • [23] Treatment of chronic migraine with Erenumab alone or as an add on therapy; a real world prospective observational study
    Boudreau, Guy P.
    Catherine, Demers
    CEPHALALGIA, 2019, 39 (1_SUPPL) : 367 - 367
  • [24] Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
    Armin Scheffler
    Olga Messel
    Sebastian Wurthmann
    Michael Nsaka
    Christoph Kleinschnitz
    Martin Glas
    Steffen Naegel
    Dagny Holle
    The Journal of Headache and Pain, 2020, 21
  • [25] Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
    Scheffler, Armin
    Messel, Olga
    Wurthmann, Sebastian
    Nsaka, Michael
    Kleinschnitz, Christoph
    Glas, Martin
    Naegel, Steffen
    Holle, Dagny
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [26] Erenumab for the treatment of refractory chronic migraine: a UK prospective real world experience
    Lambru, Giorgio
    Hill, Bethany
    Murphy, Madeleine
    Andreou, Anna P.
    CEPHALALGIA, 2019, 39 : 255 - 256
  • [27] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Alsaadi, Taoufik
    Noori, Suzan
    Varakian, Razmig
    Youssef, Saly
    Almadani, AbuBaker
    BMC NEUROLOGY, 2022, 22 (01)
  • [28] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Taoufik Alsaadi
    Suzan Noori
    Razmig Varakian
    Saly Youssef
    AbuBaker Almadani
    BMC Neurology, 22
  • [29] Real-world effectiveness data of erenumab-treated migraine patients in Switzerland: The SQUARE study
    Schafer, E.
    Arzt, M.
    Meyer, I.
    Gantenbein, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 235 - 236
  • [30] A Real-world analysis of the burden of migraine in patients with prior treatment failure: evidence from the BECOME study
    Lucas, C.
    Pozo-Rosich, P.
    Watson, D.
    Gaul, C.
    Ramsden, E.
    Ritter, S.
    Martelletti, P.
    Snellman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 801 - 801
12345